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OBJECTIVE: The purpose of this study was to compare spirometry data between patients who underwent single-lung or double-
lung transplantation the first year after transplantation. 
INTRODUCTION: Lung transplantation, which was initially described as an experimental method in 1963, has become a thera-
peutic option for patients with advanced pulmonary diseases due to improvements in organ conservation, surgical technique, im-
munosuppressive therapy and treatment of post-operative infections.
METHODS: We retrospectively reviewed the records of the 39 patients who received lung transplantation in our institution between 
August 2003 and August 2006. Twenty-nine patients survived one year post-transplantation, and all of them were followed. 
RESULTS: The increase in lung function in the double-lung transplant group was more substantial than that of the single-lung 
transplant group, exhibiting a statistical difference from the 1st month in both the forced expiratory volume in one second (FEV1) 
and the forced vital capacity (FVC) in comparison to the pre-transplant values (p <0.05).
Comparison between double-lung transplant and single lung-transplant groups of emphysema patients demonstrated a significant 
difference in lung function beginning in the 3rd month after transplantation.
DISCUSSION: The analyses of the whole group of transplant recipients and the sub-group of emphysema patients suggest the 
superiority of bilateral transplant over the unilateral alternative. Although the pre-transplant values of lung function were worse in 
the double-lung group, this difference was no longer significant in the subsequent months after surgery. 
CONCLUSION: Although both groups demonstrated functional improvement after transplantation, there was a clear tendency to 
greater improvement in FVC and FEV1 in the bilateral transplant group. Among our subjects, double-lung transplantation improved 
lung function.
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INTRODUCTION
Lung transplantation, which was initially described as 
an experimental method in 1963, has become a therapeutic 
option for patients with advanced pulmonary diseases due 
to improvements in organ conservation, surgical technique, 
immunosuppressive therapy and treatment of post-operative 
infections.
In agreement with the International Society for Heart and 
Lung Transplantation, the procedure is indicated for patients 
with advanced chronic pulmonary disease without control 
in spite of maximal medical therapy or for those for whom 
there is no efficient medical treatment.1
Initially, pulmonary fibrosis was the only indication for 
lung transplantation;2 however, indications have expanded 
to include cystic fibrosis, primary and secondary forms of 
pulmonary hypertension (PH), bronchiectasis and chronic 
obstructive pulmonary disease (COPD), primarily of the 
emphysema phenotype.3
Chronic obstructive pulmonary disease (COPD) is expected 
to be the fifth leading cause of death in the world by 20204. 
For many years, the only treatment that improved survival 520
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in patients with advanced COPD was chronic home oxygen 
therapy.5,6 Since the 1990s, orthotopic lung transplantation has 
proved to be an effective therapeutic alternative, although the 
indication for this procedure is restricted by criteria of age, co-
morbidity, and feasibility of the surgery.7 
There is a clear post-transplant survival benefit in patients 
with advanced pulmonary fibrosis and PH. In patients with 
cystic fibrosis and COPD a clear survival benefit has not 
yet been demonstrated, but the post-transplantation gain in 
quality of life and in physical activities tolerance appears to 
be more important.8-12 We have also demonstrated that post-
transplantation bronchial stenosis can be corrected with a 
self-expandable silicone stent.13
The lung transplant program at our institution began 
in 1990. This program has experienced irregular patient 
turnover and inactive periods. Between 1990 and 2003, 
20 single-lung transplantations were performed. Between 
2003 and 2007, when a permanent and exclusive team was 
created, our institution performed 60 transplants. Of those 60 
procedures, 36 were double-lung transplants. We performed 
an annual mean of 15 transplants between 2006 and 2007. 
When lung transplantation is indicated, a unilateral or 
bilateral transplantation may be carried out. Single-lung surgery 
maintains a native lung, whereas double-lung transplants require 
the removal of both native lungs from the receiver.
Double lung transplant is a necessity for suppurative 
diseases that attack both native lungs. In these cases, the 
persistence of an infected lung in a transplanted individual 
who needs immunosuppressive therapy can lead to infectious 
exacerbations and risk of respiratory complications, such 
as chronic sputum production and progressive physical 
limitation after the operation.
Since the unilateral transplant technique is easier and 
requires less surgical time, patients with non-suppurative 
diseases like emphysema and pulmonary fibrosis often 
initially undergo this procedure.14 However, even in 
non-suppurative diseases, there seems to be prolonged 
improvement when bilateral transplants are performed. For 
example, in patients with COPD who underwent bilateral 
lung transplantation, superior lung function and a trend 
towards improved long-term survival were observed despite 
apparent equity between the two methods when exercise 
tolerance and quality of life were assessed.3,15 
Since its initial description, the survival of lung 
transplantation patients has increased. At present, some 
centers report one-year survival in excess of 80%, with an 
average of 60% survival after 3 years. With this increase 
in life expectancy, it is important to study the methods of 
follow-up and long-term control in order to quickly and 
precisely diagnose infectious complications and rejection.16 
Spirometry is used in the follow-up of transplanted 
patients. The evaluation of FEV1 and FVC is a reproducible 
method for screening for complications including rejection, 
bronchiolitis obliterans and infection. This method has a low 
diagnosis specificity regarding the type of complication.
In case of unilateral transplants, there is an additional 
pitfall in the interpretation of spirometric data. An observed 
decrease in FEV1 can be a consequence of complications in 
the transplanted lung as well as progression of the disease or 
hyperinsufflation in the native lung.
Decreases in FVC and FEV1 greater than 11% and 
12%, respectively, are considered significant for bilateral 
transplantation. In comparison, decreases in the FVC and FEV1 
of greater than 12% and 13%, respectively, are considered 
significant for unilateral transplantation. Such decreases 
mandate investigation of rejection or infection of the organ.17
As noted previously, the surgical technique for bilateral 
transplantation is more laborious than that for unilateral 
transplantation. However, if this procedure presents long-
term advantages for the transplanted patient, this operation 
is indicated. The advantages of bilateral transplantation 
in patients with non-suppurative pulmonary diseases have 
not been confirmed. Recent data show that spirometry 
following double-lung transplantation is marginally superior 
to that following single-lung transplantation in patients with 
emphysema.18 
The purpose of this study was to compare spirometry data 
between patients who underwent single-lung and double-lung 
transplantation at the first year after the transplant procedure. 
We intend to determine whether bilateral lung transplantation 
conveys a larger gain in pulmonary function and whether this 
advantage persists after one year of follow-up. These results 
will contribute to the growing evidence that bilateral lung 
transplantation is superior to the unilateral alternative. 
METHODS
We retrospectively reviewed the records of the 39 
patients who underwent lung transplantation in our 
institution between August 2003 and August 2006. Twenty-
nine of the patients survived to one year after surgery, and 
all of them were followed. Another 10 patients (9 single-
lung transplantation and 1 double-lung transplantation) died 
within the first post-operative year. These patients were 
excluded from the study. 
The follow-up after hospital discharge was carried out 
weekly until the end of the third month, after which it was 
conducted monthly or twice-monthly. In all visits, the patient 
was evaluated by the performance of pulmonary function 
tests, a radiological examination and blood tests.
The immunosuppressive therapy regimen used by our 
group consists of induction with Basiliximab (Simulect) 521
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for suppurative patients and 1 gram of metilprednisolone 
intraoperatively for all patients. The maintenance regimen 
consists of tacrolimus, azathioprine and steroids. If the 
patient is intolerant to tacrolimus, they receive cyclosporine 
instead. In addition, azathioprine can be replaced with 
mycophenolate mofetil. The standard treatment for acute 
rejection is 10 mg/kg pulse therapy with metilprednisolone.
All patients underwent monthly vigilance bronchoscopies 
for the first twelve months after transplantation. We collected 
biopsies and bronchoalveolar lavage in order to identify 
rejection and infections. After this period, the bronchoscopies 
were performed according to clinical indication.
The spirometric values of these 29 patients who achieved 
more than 1 year survival after lung transplantation were 
analyzed. The FVC and FEV1 values were analyzed as the 
percent of predicted value from the last test performed before 
transplantation. These tests were performed at 1 month, 
3 months, 6 months, 9 months and one year following 
transplantation.
All spirometric measurements were carried out in 
accordance with the guidelines of the International 
Proceedings in Portable Spirometer (Koko Spirometry; 
Pulmonary Data Services Instrumentation, Inc, Louisville, 
Lap) or Pletsmograph (MedGraphics Elite Dx System, St 
Paul, MN). The results are expressed in absolute values 
and percentage of the predicted value using the equations 
reported by Knudson et al.19 All tests were carried out in the 
morning (Mondays from 8:30 to 11:30 am).20 
The patients were divided into two groups according 
to the type of lung transplant. The single-lung group 
included 11 patients, and the double-lung group included 
18 patients. 
Each measurement passed a normality test (Kolmogorov-
Smirnov). The spirometric evolution of each group from pre-
transplant up to one year post-operation was compared using 
analysis of variance (ANOVA). The comparative analysis 
between unilateral and bilateral transplants at each time 
point was performed by a students t-test for comparison of 
averages. The value of significance was alpha = 0.05.
The sub-group of pulmonary emphysema patients (five 
unilateral transplants and four bilateral transplants) was 
analyzed separately with the same statistical methodology. 
The statistical calculations were carried out by use of Sigma 
Plot V10.0 (SPSS, Chicago, IL).
RESULTS
Demographic characteristics and lung function pre-
transplantation
The lung function of eighteen patients who underwent 
bilateral lung transplantation and eleven patients who 
received unilateral transplants were analyzed. Table 1 
shows the baseline data of each group of patients. There 
was a difference in the FVC and FEV1 on the pre-transplant 
spirometry between unilateral and bilateral transplant 
recipients (p=0.002 and p<0.001, respectively). The patients 
who underwent double-lung transplantation had worse 
lung function pre-transplantation. The FVC of transplanted 
double-lung recipients was, on average, 14% less than in the 
unilateral transplant group. The difference of the preoperative 
FEV1 was 11%. The median age of the two groups was also 
different; unilateral transplant recipients averaged 13 years 
older than bilateral recipients (p=0.005).
Regarding the underlying disease, the single-lung 
transplant group contained a higher number of pulmonary 
fibrosis patients, while the double-lung transplant group 
consisted of more patients with cystic fibrosis, bronchiectasis, 
lymphangioleiomyomatosis and PH. Pulmonary emphysema 
was the only condition with similar numbers of unilateral 
and bilateral recipients in our cohort.
Post-transplant lung function evolution
Table 3 shows the mean values for FVC and FEV1 
percent predicted in both single- and double-lung transplant 
recipients during follow-up.
The increase in lung function in the double-lung transplant 
group was more marked, showing a statistical difference from 
the 1st month in both the FEV1 (Figure 1) and FVC (Figure 
Table 1 - Demographic data of lung transplant recipients: 
Single- vs. Double-lung transplant. (alpha = 0.05)
Single Lung 
N=11 
Double Lung 
N=18
 
Sex 4F, 7M 5F, 13M p = 0.694
Age (y) 53.9 +/- 7.10 40.83 +/- 12.86 p = 0.005
Height (cm) 160 +/- 9.06 164 +/- 8.0 p = 0.206
Weight (Kg) 61.09 +/- 10.75 58.55 +/- 12.32 p = 0.578
FVC % 54.27 +/- 7.70 40.23 +/- 12.45 p = 0.002
FEV1% 44.11 +/- 18.59 23.68 +/- 9.18 p < 0.001
Disease     p = 0.007
Emphysema 5 4
Pulmonary Fibrosis 6 1
Bronchiectasis  6
Cystic Fibrosis  5
Lymphangioleiomyo-
matosis
1
Pulmonary 
Hypertension 
  1522
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2) in comparison to the pre-transplant values (p <0.05). The 
FVC of this group continued to increase during the first post-
operative year. We observed a significant increase between 
the values in the 9th and 12th month as compared with the first 
post-operative month (p <0.05).
In the single-lung transplant group, there was significant 
increase of FVC after 3 months (p=0.002) and FEV1 after  6 months (p=0.004). After 3º and 6º months, the FVC and 
FEV1 of the unilateral group did not vary significantly, 
respectively. 
Comparison of FEV1 and FVC post-transplant values (1, 
3, 6, 9 and 12 months) between the unilateral and bilateral 
transplant groups did not show any statistically significant 
differences. Both groups improved from a functional point 
of view.
The bilateral transplant group had a proportionally 
higher gain since their pre-transplant lung function was 
more compromised. In double-lung transplant recipients, the 
FEV1 increased 3.75-fold from pre-transplantation values 
at 12 months post-transplantation. By contrast, a 1.66-fold 
increase was observed in the single-lung group over the 
same period of time (p<0.001). The FVC increased 2.14-
fold in the bilateral group versus a 1.37-fold increase in the 
unilateral group (p<0.001).
Sub-group of emphysema patients
During the period analyzed in our study, nine patients 
Table 2 - Demographic data of lung transplant emphysema recipients: Single- vs. Double-lung transplant (alpha=0.05)
Variable Transplant PRE 1 mo. 3 mo. 6 mo. 9 mo. 12 mo.
FVC Single 55,71%** 65,55% 73,99%* 76,66%* 79,01%* 77,37%*
Double 40,37% 59,06%* 72,22%* 76,10%* 81,64%* 82,31%*
FEV1 Single 44,11%** 61,55% 64,26%* 67,39%* 70,86%* 70,29%*
Double 23,72% 62,41%* 76,53%* 78,13%* 82,17%* 85,41%*
Table 3 - Lung Function values in all single and double lung 
transplant recipients during follow-up
Single Lung 
N=5 
Double Lung N=4
Sex 3F, 2M 4M p = 1.000
Age (y) 52.2 +/- 8.13 56.25 + / - 6.39 p = 0.444
Height (cm) 155 +/- 9.0 165 +/- 7.1 p = 0.128
Weight (Kg) 55.4 +/- 7.4 63.8 +/- 16.2 p = 0.331
FVC % 52.98 +/- 8.70 51.02 +/- 11.73 p = 0.781
FEV1% 27.15 +/- 5.58 21.08 +/- 4.75  p = 0.128
Values expressed in % predicted value. ** Statistically significant differ-
ence between single and double transplant groups. * Statistically signifi-
cant difference compared to pre-transplant values.  Alpha = 0.05
Figure 1 - Forced vital capacity of lung transplant recipients (Single- vs. 
Double-lung transplant group)
Figure 3 - Forced vital capacity of lung transplant recipients with emphysema 
(Single- vs. Double-lung transplant group)523
CLINICS 2009;64(6):519-25 Spirometric assessment of lung transplant patients
Pêgo-Fernandes PM et al.
with pulmonary emphysema underwent pulmonary 
transplantation, five single-lung and four double-lung 
transplants. We compared the two techniques in this sub-
group of patients.
When the pre-transplant variables of each group were 
compared, there was no observed difference in age, height, 
weight or pulmonary function (Table 2).
Figures 3 and 4 show the evolution of the functional 
data (FVC and FEV1) during the one year follow-up of the 
emphysema patients subjected to lung transplantation. There 
was no significant variation in the FVC in the unilateral 
group during the post-transplant months in comparison with 
pre-transplant values (p=0.861). For the same group, the 
post-transplant FEV1 values increased from the sixth month 
post-transplantation onwards (p=0.002). The double-lung 
transplant group showed significant increases in FVC and 
FEV1 from the third month post-transplantation onwards (p 
<0.001 and p=0.002).
Comparisons between the two groups show a difference 
in lung function beginning in the third month post-
transplantation. The unilateral transplant group had an 
average FVC of 72.7 + 5.8% of the predicted value, and the 
bilateral group had an average of 96.8 + 5.6% (p=0.001) 
of the predicted value. This finding is reproducible when 
comparing FEV1: the value for the unilateral group was 53.4 
+ 15.1 % of predicted value and the value for the bilateral 
group was 99.1 + 22.2% of the predicted value (p=0.015). 
The difference in lung function between the groups was 
maintained in all follow up measurements.
DISCUSSION
This study compared the spirometric evolution of single- 
and double-lung transplant patients in the first year after 
surgery. The results of the analyses of the whole group and 
the sub-group of emphysema patients suggest the superiority 
of bilateral transplantation over the unilateral alternative.
The values of the FVC and FEV1 pre-transplantation 
were lower in patients who underwent double-lung 
transplantation when compared to unilateral transplantation. 
This difference is explained by the selection of younger 
and more functionally impaired patients, such as those 
with cystic fibrosis and bronchiectasis, for the bilateral 
procedure.
Although the pre-transplant lung function values 
were worse in the double-lung transplantation group, this 
difference was not observed in the months following surgery. 
After one year of follow-up, we observed an average 2.14-
fold gain in the initial value of the FVC and a 3.75-fold 
increase in the FEV1 in bilateral transplant patients. By 
contrast, we observed a 1.37-fold increase in the initial FVC 
value and a 1.66-fold increase in the FEV1 in unilateral 
transplant recipients. (P=0.004 and P=0.001, respectively).
Despite the initial disparities in lung function, we 
demonstrated equality between the groups at one month 
post-transplantation. This equality persisted through the 
end of the first year. There were no statistically or clinically 
significant differences between these groups. In summary, in 
spite of worse initial lung function, double-lung transplant 
patients exhibited functional performance, as measured by 
spirometry, that was equal to or better than the single-lung 
recipients during the observed period of follow-up.
Figure 2 - Forced expiratory volume in one second of lung transplant re-
cipients (Single- vs. Double-lung transplant group)
Figure 4 - Forced expiratory volume in one second of lung transplant recipi-
ents with emphysema (Single- vs. Double-lung transplant group)524
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In our analysis of the group of emphysema patients, we 
compared the two transplant modalities in patients with 
similar anthropometric characteristics and preoperative 
function. In those patients with similar characteristics, the 
double-lung transplant patients showed greater increase in 
lung function relative to the single-lung recipients from the 
3rd month post-transplantation.
There  is  no  consensus  on  the  ideal  timing  of 
transplantation in patients with COPD. The current 
recommendation is to include only patients with severe 
COPD and respiratory insufficiency. This suggestion is 
the most appropriate because of the high rate of associated 
mortality in this population.10,11
Approximately 40% of pulmonary transplants are 
currently carried out for advanced pulmonary emphysema.16 
It is not clearly established whether bilateral transplantation 
is advantageous in this group. However, for single-lung 
transplantation, evidence suggests that hyperinsufflation of 
the native lung can lead to an imbalance in the ventilation 
/ perfusion ratio and serious negative hemodynamic 
consequences.21 The literature indicates that single-lung 
transplantation has a higher mortality rate than double-lung 
transplantation. The risk of death in emphysema patients 
receiving a single-lung transplant was nine-fold higher than 
in the patients who underwent the bilateral procedure.15 In 
addition, the improved long-term survival of double-lung 
over single-lung recipients among patients with emphysema 
remains a favorable prognostic factor in the International 
Society of Heart and Lung Transplantation (ISHLT) 
registry.16
In our study, patients with emphysema presented with 
pre-operative values for FVC and FEV1 that were similar 
to those reported in the literature. A series of 306 recipients 
reported by Cassivi et al showed mean FVC and FEV1 of 
51% and 16% of the predicted values, respectively.22 In 
the study above cited, the mean values increased to 84% 
and 79% of the predicted values at the end of the 1 year 
follow-up. The difference in these values is significant. 
Our study demonstrated a significant increase of the same 
values, but the increases in FEV1 and FVC in double-lung 
transplantation were observed from the third month post-
transplantation onwards. In single-lung transplants, six 
months were required before a significant difference in FEV1 
was observed. Ferrer et al7 reported that mean values for FVC 
and FEV1 were 41.8% and 21.1% of the predicted values in 
a sample of 65 patients with emphysema. One must consider, 
however, that patients who underwent single-lung transplant 
may have exhibited worse performance in the post-operative 
examinations due to persistence and progression of disease 
in the native lung . 
Another factor associated with the single lung transplant 
functional performance might be hyperinflation of the 
remaining lung. Hyperinflation of the native lung is defined 
as swinging of the mediastinum towards the grafted lung 
with rectification of the ipsilateral diaphragm. Hyperinflation 
leads to a mechanical disadvantage for ventilation and can 
cause hemodynamic worsening due to increased thoracic 
pressure. Hyperinflation is associated with low FVC and 
FEV1 values in unilateral transplantation, especially in 
patients with obstructive diseases.23
Better spirometry results were obtained for bilateral-lung 
transplant recipients. Hyperinflation of the native lung may 
explain the reduced functional values observed for single-
lung recipients. Pulmonary fibrosis is another disease that 
was treated with double-lung transplantation. Based on 
the results of this study, it is unclear whether patients with 
PF exhibit similar functional outcomes to those observed 
in patients with emphysema, as our cohort contained six 
patients who underwent double-lung transplantation and 
only one who underwent single-lung transplantation. 
However, when both lungs are replaced in bilateral 
transplantation, the influence of the pulmonary disease on 
post-operative functional performance is reduced.
In conclusion, we observed significant improvement of 
lung function in unilateral and bilateral transplant recipients 
after one year of follow-up. There was a clear tendency 
of greater improvement in FVC and FEV1 in the bilateral 
transplant group. Evaluation of a larger patient population 
and longer follow-up are necessary in order to confirm these 
observations.
REFERENCES
1.  Maurer JR, Frost AE, Estenne M, Higenbottam T, Glanville AR. 
International guidelines for the selection of lung transplant candidates. 
The International Society for Heart and Lung Transplantation, the 
American Thoracic Society, the American Society of Transplant 
Physicians, the European Respiratory Society. Transplantation. 
1998;15;66:951-6.
2.  The Toronto Lung Transplant Group. Experience with single-lung 
transplantation for pulmonary fibrosis. JAMA. 1988;15;259:2258-62.
3.  Pochettino A, Kotloff RM, Rosengard BR, Arcasoy SM, Blumenthal 
NP, Kaiser LR, et al. Bilateral versus single lung transplantation for 
chronic obstructive pulmonary disease: intermediate-term results. Ann 
Thorac Surg. 2000;70:1813-8; discussion 1818-9.525
CLINICS 2009;64(6):519-25 Spirometric assessment of lung transplant patients
Pêgo-Fernandes PM et al.
4.  Murray CJ, Lopez AD. Alternative projections of mortality and 
disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 
1997;24;349:1498-504.
5.  Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen 
therapy in hypoxemic chronic obstructive lung disease: a clinical trial. 
Ann Intern Med. 1980;93:391-8.
6.  Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale 
complicating chronic bronchitis and emphysema. Report of the Medical 
Research Council Working Party. Lancet. 1981;28;1:681-6.
7.  Ferrer J, Rodriguez E, Roman A, Bravo C, Roldan J, Hermosilla E, et 
al. Factors related to postoperative mortality in lung transplantation for 
emphysema. Transplant Proc. 2007;39:3317-22.
8.  Chu CM, Chan VL, Lin AW, Wong IW, Leung WS, Lai CK. Readmission 
rates and life threatening events in COPD survivors treated with non-
invasive ventilation for acute hypercapnic respiratory failure. Thorax. 
2004;59:1020-5.
9.  Geertsma A, Ten Vergert EM, Bonsel GJ, de Boer WJ, van der Bij W. 
Does lung transplantation prolong life? A comparison of survival with 
and without transplantation. J Heart Lung Transplant. 1998;17:511-6.
10.  Thabut G, Mal H, Castier Y, Groussard O, Brugiere O, Marrash-Chahla 
R, et al. Survival benefit of lung transplantation for patients with 
idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg. 2003;126:469-
75.
11.  Charman SC, Sharples LD, McNeil KD, Wallwork J. Assessment of 
survival benefit after lung transplantation by patient diagnosis. J Heart 
Lung Transplant. 2002;21:226-32.
12.  Hosenpud JD, Bennett LE, Keck BM, Edwards EB, Novick RJ. Effect 
of diagnosis on survival benefit of lung transplantation for end-stage 
lung disease. Lancet. 1998;3;351:24-7.
13  Samano MN, Minamoto H, Oliveira EQ, Caramori ML, Pêgo-Fernandes 
PM, Jatene FB. Bronchial stenosis treatment after lung transplantation 
with a self-expandable silicone stent. Clinics. 2007;62:643-644.
14.  Mal H, Andreassian B, Pamela F, Duchatelle JP, Rondeau E, Dubois F, et 
al. Unilateral lung transplantation in end-stage pulmonary emphysema. 
Am Rev Respir Dis. 1989;140:797-802.
15.  Angles R, Tenorio L, Roman A, Soler J, Rochera M, de Latorre FJ. 
Lung transplantation for emphysema. Lung hyperinflation: incidence 
and outcome. Transpl Int. 2005;17:810-4.
16.  Trulock EP, Christie JD, Edwards LB, Boucek MM, Aurora P, Taylor 
DO, et al. Registry of the International Society for Heart and Lung 
Transplantation: twenty-fourth official adult lung and heart-lung 
transplantation report-2007. J Heart Lung Transplant. 2007;26:782-
95.
17.  Martinez JA, Paradis IL, Dauber JH, Grgurich W, Richards T, Yousem 
SA, et al. Spirometry values in stable lung transplant recipients. Am J 
Respir Crit Care Med. 1997;155:285-90.
18.  Mason DP, Rajeswaran J, Murthy SC, McNeill AM, Budev MM, Mehta 
AC, et al. Spirometry after transplantation: how much better are two 
lungs than one? Ann Thorac Surg. 2008;85:1193-201, 201 e1-2.
19.  Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the 
normal maximal expiratory flow-volume curve with growth and aging. 
Am Rev Respir Dis. 1983;127:725-34.
20.  Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, 
et al. General considerations for lung function testing. Eur Respir J. 
2005;26:153-61.
21.  Stevens PM, Johnson PC, Bell RL, Beall AC, Jr., Jenkins DE. Regional 
ventilation and perfusion after lung transplantation in patients with 
emphysema. N Engl J Med. 1970 29;282:245-9.
22.  Cassivi SD, Meyers BF, Battafarano RJ, Guthrie TJ, Trulock EP, 
Lynch JP, et al. Thirteen-year experience in lung transplantation for 
emphysema. Ann Thorac Surg. 2002;74:1663-9; discussion 9-70.
23.  Yonan NA, el-Gamel A, Egan J, Kakadellis J, Rahman A, Deiraniya 
AK. Single lung transplantation for emphysema: predictors for native 
lung hyperinflation. J Heart Lung Transplant. 1998;17:192-201.
 